Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Novel psychoactive substances : classification, pharmacology and toxicology / / edited by Paul I. Dargan, David M. Wood
| Novel psychoactive substances : classification, pharmacology and toxicology / / edited by Paul I. Dargan, David M. Wood |
| Pubbl/distr/stampa | London, : Academic Press, c2013 |
| Descrizione fisica | 1 online resource (xiv, 423 pages) : illustrations (some color) |
| Disciplina | 615.78 |
| Collana | Gale eBooks |
| Soggetto topico |
Psychotropic drugs
Psychopharmacology Substance abuse Neuropharmacology |
| ISBN | 0-12-415911-7 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Novel Psychoactive Substances: Classification, Pharmacology and Toxicology; Copyright Page; Contents; Forewords; List of Contributors; 1 Background; 1. Legal Classification of Novel Psychoactive Substances; Introduction; Historical Background; Legal Concerns; Chemical and Pharmacological Classification; Traditional Control Mechanisms; Specific Listing; Generic Definitions; The Analogue Approach; Recent Developments; Temporary Listing; New Zealand: Class D; UK: Importation Controls; Ireland: Criminal Justice (Psychoactive Substances) Act 2010; Japan: Non-authorised Pharmaceuticals
Switzerland: Schedule 'e'Poland, Romania: Substitute Drugs; Finland: Intoxication and Harm; Medicines Legislation; Consumer Protection Legislation; International-level Initiatives; Other Control Options and Future Developments; References; 2. Monitoring Novel Psychoactive Substances; Introduction; Definitions; The Identification, Risk Assessment and Monitoring of Novel Psychoactive Substances; The EU Ews Information Exchange; Risk Assessment; Case Study: Mephedrone Risk Assessment; National European EWS Networks; The UK EWS; The French EWS; The Nordic Countries: Nordic-NADiS International, Regional and National Drug Monitoring SystemsNational Drug Monitoring Systems; USA; Australia; New Zealand; South Africa; The United Nations System; World Health Organisation (WHO); United Nations Global SMART Programme; Inter-American Observatory on Drugs; Sources for Detecting and Monitoring Novel Psychoactive Substances; Forensic Science; Pill Testing; Wastewater Analysis and Pooled Urine Analysis; Computational Modelling; Hospital Emergencies Data; Internet Monitoring; Surveys and Studies on the Prevalence of Use of Novel Psychoactive Substances; Conclusions; References 3. Availability and Supply of Novel Psychoactive SubstancesBackground; Novel Psychoactive Substance Market; NPS Origins and Market Entry; NPS Market Structure; Supply Chain: Manufacturing and Distribution; Sale of NPS; Internet; Retail Vendors; Street Level Drug Dealers; Products; Pricing of NPS; Transaction Mechanisms; Marketing; Branding and Packaging; Misbranding; Market Dynamics; Conclusions; References; 4. Epidemiology of Use of Novel Psychoactive Substances; Introduction; General Population Surveys; Surveys in Young People; Adult Population Surveys Non-probabilistic Convenience Sample SurveysMephedrone; Synthetic Cannabinoid Receptor Agonists; Salvia divinorum; Behavioural Epidemiology; Data from Medical Monitoring Systems; Alternative Methodologies to Assess Prevalence of NPS; Summary and Conclusions; References; 5. Social Issues in the Use of Novel Psychoactive Substances; Introduction; Availability; Prevalence in Context: Differentiated Demand in Different Leisure Venues; School and College Students; Bar Customers; Festival-goers; Dance Club Customers; Understanding Motivations: the Displacement Question Exploring Social Harms: Legislative Control and the Supply of Nps |
| Record Nr. | UNINA-9910790563103321 |
| London, : Academic Press, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Novel psychoactive substances : classification, pharmacology and toxicology / / edited by Paul I. Dargan, David M. Wood
| Novel psychoactive substances : classification, pharmacology and toxicology / / edited by Paul I. Dargan, David M. Wood |
| Pubbl/distr/stampa | London, : Academic Press, c2013 |
| Descrizione fisica | 1 online resource (xiv, 423 pages) : illustrations (some color) |
| Disciplina | 615.78 |
| Collana | Gale eBooks |
| Soggetto topico |
Psychotropic drugs
Psychopharmacology Substance abuse Neuropharmacology |
| ISBN | 0-12-415911-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Novel Psychoactive Substances: Classification, Pharmacology and Toxicology; Copyright Page; Contents; Forewords; List of Contributors; 1 Background; 1. Legal Classification of Novel Psychoactive Substances; Introduction; Historical Background; Legal Concerns; Chemical and Pharmacological Classification; Traditional Control Mechanisms; Specific Listing; Generic Definitions; The Analogue Approach; Recent Developments; Temporary Listing; New Zealand: Class D; UK: Importation Controls; Ireland: Criminal Justice (Psychoactive Substances) Act 2010; Japan: Non-authorised Pharmaceuticals
Switzerland: Schedule 'e'Poland, Romania: Substitute Drugs; Finland: Intoxication and Harm; Medicines Legislation; Consumer Protection Legislation; International-level Initiatives; Other Control Options and Future Developments; References; 2. Monitoring Novel Psychoactive Substances; Introduction; Definitions; The Identification, Risk Assessment and Monitoring of Novel Psychoactive Substances; The EU Ews Information Exchange; Risk Assessment; Case Study: Mephedrone Risk Assessment; National European EWS Networks; The UK EWS; The French EWS; The Nordic Countries: Nordic-NADiS International, Regional and National Drug Monitoring SystemsNational Drug Monitoring Systems; USA; Australia; New Zealand; South Africa; The United Nations System; World Health Organisation (WHO); United Nations Global SMART Programme; Inter-American Observatory on Drugs; Sources for Detecting and Monitoring Novel Psychoactive Substances; Forensic Science; Pill Testing; Wastewater Analysis and Pooled Urine Analysis; Computational Modelling; Hospital Emergencies Data; Internet Monitoring; Surveys and Studies on the Prevalence of Use of Novel Psychoactive Substances; Conclusions; References 3. Availability and Supply of Novel Psychoactive SubstancesBackground; Novel Psychoactive Substance Market; NPS Origins and Market Entry; NPS Market Structure; Supply Chain: Manufacturing and Distribution; Sale of NPS; Internet; Retail Vendors; Street Level Drug Dealers; Products; Pricing of NPS; Transaction Mechanisms; Marketing; Branding and Packaging; Misbranding; Market Dynamics; Conclusions; References; 4. Epidemiology of Use of Novel Psychoactive Substances; Introduction; General Population Surveys; Surveys in Young People; Adult Population Surveys Non-probabilistic Convenience Sample SurveysMephedrone; Synthetic Cannabinoid Receptor Agonists; Salvia divinorum; Behavioural Epidemiology; Data from Medical Monitoring Systems; Alternative Methodologies to Assess Prevalence of NPS; Summary and Conclusions; References; 5. Social Issues in the Use of Novel Psychoactive Substances; Introduction; Availability; Prevalence in Context: Differentiated Demand in Different Leisure Venues; School and College Students; Bar Customers; Festival-goers; Dance Club Customers; Understanding Motivations: the Displacement Question Exploring Social Harms: Legislative Control and the Supply of Nps |
| Record Nr. | UNINA-9910822185203321 |
| London, : Academic Press, c2013 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Pharmacology of the WNT signaling system / / Gunnar Schulte, Pawel Kozielewicz, editors
| Pharmacology of the WNT signaling system / / Gunnar Schulte, Pawel Kozielewicz, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (420 pages) |
| Disciplina | 572.64 |
| Collana | Handbook of experimental pharmacology |
| Soggetto topico |
Wnt proteins
Neuropharmacology Pharmacology Farmacologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-85499-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910508448003321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
| Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly |
| Autore | Kelly John <1961-> |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615/.78 |
| Soggetto topico |
Neuropharmacology
Drug development |
| ISBN |
1-282-36283-6
9786612362835 0-470-68292-2 0-470-68291-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease 4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References 6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction 7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology 8.5 Toxicology studies required for regulatory purposes |
| Record Nr. | UNINA-9910139897403321 |
Kelly John <1961->
|
||
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly
| Principles of CNS drug development [[electronic resource] ] : from test tube to patient / / John Kelly |
| Autore | Kelly John <1961-> |
| Pubbl/distr/stampa | Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 |
| Descrizione fisica | 1 online resource (326 p.) |
| Disciplina | 615/.78 |
| Soggetto topico |
Neuropharmacology
Drug development |
| ISBN |
1-282-36283-6
9786612362835 0-470-68292-2 0-470-68291-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Principles of CNS drug development; Contents; Acknowledgements; Preface; Abbreviations; 1 Introduction; 1.1 The global burden of CNS disease; 1.2 Assessment of the global burden of disease; 1.3 The prevalence of CNS disorders; 1.4 Disability due to CNS disorders; 1.5 Economic Costs; 1.6 Concluding comments; References; 2 An overview of the major CNS disorders; 2.1 Introduction; 2.2 Overview of psychiatric disorders; 2.3 Overview of neurological/neurodegenerative disorders; 2.4 Concluding comments; References; 3 Neurobiological substrates of CNS disorders; 3.1 Introduction
3.2 Brief introduction to the principles of chemical neurotransmission3.3 Stages of chemical neurotransmission; 3.4 Approaches to investigating CNS alterations in CNS disorders; 3.5 Evidence for a neurobiological rationale for CNS disorders; 3.6 Concluding comments; References; 4 Current pharmacological targets; 4.1 Introduction; 4.2 Pharmacological treatments for depression; 4.3 Pharmacological treatments for schizophrenia; 4.4 Pharmacological treatments for anxiety disorders; 4.5 Pharmacological treatments for epilepsy; 4.6 Pharmacological treatments for Parkinson's disease 4.7 Pharmacological treatments for Alzheimer's disease4.8 Concluding comments; References; 5 Premarketing efficacy evaluation; 5.1 Introduction; 5.2 Target identification; 5.3 Lead optimisation; 5.4 Target validation in animal models; 5.5 The use of genetically modified animals in CNS drug development; 5.6 A selection of animal models of psychiatric disease; 5.7 A selection of animal models of neurodegenerative disease; 5.8 Which models to choose; 5.9 Clinical trials that evaluate drug efficacy; 5.10 Specific drug profiles; References 6 Pharmacokinetic considerations: Absorption, distribution, metabolism and elimination6.1 Introduction; 6.2 What are the 'ideal' pharmacokinetic properties for a CNS drug?; 6.3 Absorption; 6.4 Distribution; 6.5 Metabolism; 6.6 Elimination; 6.7 Measurement of drug concentrations; 6.8 Factors that affect pharmacokinetics; 6.9 Allometric scaling; 6.10 Microdosing (Phase 0) Studies; 6.11 Dose prediction and therapeutic drug monitoring; 6.12 Stereoselectivity of metabolism of drugs; 6.13 Specific drug profiles; 6.14 Concluding comments; References; 7 Safety concerns; 7.1 Introduction 7.2 Postmarketing surveillance7.3 Acute poisoning; 7.4 Quantification of the relative risk of fatalities from CNS drugs; 7.5 Adverse drug reactions (ADRs); 7.6 Specific types of toxicity encountered with psychotropic drugs; 7.7 Safety concerns following long-term administration of CNS Drugs; 7.8 Polypharmacy; 7.9 Specific drug profiles; 7.10 Concluding comments; References; Websites; 8 Preclinical and clinical safety evaluation; 8.1 Introduction; 8.2 Preclinical exploratory toxicology and safety pharmacology evaluations; 8.3 Primary and secondary pharmacology; 8.4 Safety pharmacology 8.5 Toxicology studies required for regulatory purposes |
| Record Nr. | UNINA-9910817296903321 |
|
Kelly John <1961->
|
||
| Chichester, West Sussex ; ; Hoboken, NJ, : J. Wiley, 2009 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Progress in neurotherapeutics and neuropsychopharmacology
| Progress in neurotherapeutics and neuropsychopharmacology |
| Pubbl/distr/stampa | Cambridge [England], : Cambridge University Press, 2006-2008 |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Neuropsychopharmacology
Neurobehavioral disorders Neurology Brain Diseases - drug therapy Neuropharmacology Central Nervous System - drug effects Clinical Trials as Topic Mental Disorders - drug therapy |
| Soggetto genere / forma | Periodicals. |
| Soggetto non controllato | Pharmacy, Therapeutics, & Pharmacology |
| ISSN | 1748-233X |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Neurotherapeutics and neuropsychopharmacology |
| Record Nr. | UNISA-996336652303316 |
| Cambridge [England], : Cambridge University Press, 2006-2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Psychopharmacology Reconsidered [[electronic resource] ] : A Concise Guide Exploring the Limits of Diagnosis and Treatment / / by Robert Haim Belmaker, Pesach Lichtenberg
| Psychopharmacology Reconsidered [[electronic resource] ] : A Concise Guide Exploring the Limits of Diagnosis and Treatment / / by Robert Haim Belmaker, Pesach Lichtenberg |
| Autore | Belmaker Robert Haim |
| Edizione | [1st ed. 2023.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
| Descrizione fisica | 1 online resource (218 pages) |
| Disciplina | 830 |
| Soggetto topico |
Psychiatry
Neurology Neuropharmacology Nervous system - Diseases Diagnosis Therapeutics Neurological Disorders |
| ISBN | 3-031-40371-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Acknowledgements -- Contents -- Chapter 1: Introduction -- References -- Chapter 2: The Biochemical Basis for Psychopharmacology in the Brain Synapse: Are We Looking in the Right Place? -- Reference -- Chapter 3: Are DSM or ICD Diagnoses the Basis for Scientific Use of Psychopharmacologic Drugs? -- References -- Chapter 4: The Clinical Control Trial in Psychiatry: What It Is, What It Has Been, and Does It Have a Future? -- Post-hoc Analyses -- Acute Trials, Prevention Trials, "Survival Trials" and Crossover Trials -- The Role of the Clinical Trial in the Teaching of Psychopharmacology -- Individual Differences -- Advice for the Clinical Reader of Controlled Trials -- Add-On Vs. Placebo Controlled Trials -- The Role of Guidelines -- Pathways for the Future -- References -- Chapter 5: Antidepressant Drugs: For Anyone Sad or Only for the Melancholic Depressed? -- Maintenance Treatment with Antidepressants -- The Development of SSRIs AND SNRIs -- The Monoamine Theories of Depression -- Monoamine Oxidase Inhibitors -- Bipolar Depression -- Antidepressants in Panic Disorder -- Switching Antidepressants in Treatment Resistance -- Cortisol and Depression -- Side Effects -- Pregnancy and Lactation -- Animal Models and Depression Psychopharmacology -- Stimulants in Depression -- Antidepressants in Depression After Myocardial Infarction -- Antidepressants and COVID-19 -- Psychological Effects of Antidepressant Treatment -- Clinical Vignettes -- References -- Chapter 6: Antipsychotic Drugs: Do They Define Schizophrenia or Do They Blunt All Emotions? -- Rating Scales -- Pharmacodynamics -- The Disease Model -- Mechanisms of Action -- The Dopamine Hypothesis -- New Antipsychotics -- Philosophy of Antipsychotic Treatment -- Doses -- Side Effects -- Clinical Vignettes -- References.
Chapter 7: Antianxiety Medications: Are They Addictive or Are They Mankind's Precious Heritage? -- Historical Background -- The Nonlinear Nature of Anti-anxiety Treatment -- Alcohol as a Proto Anti-anxiety Drug -- Non-barbiturate Sedatives -- Benzodiazepines -- The Mechanism of Action of Benzodiazepines -- The Z Drugs -- Comparison of Treatment of Anxiety with Benzodiazepines Vs. Antidepressants -- Side Effects -- Sleep Architecture -- Benzodiazepine Use in Psychiatry-Related Medicine -- Pregnancy and Lactation -- Clinical Vignettes -- References -- Chapter 8: Mood Stabilizers: Off the Gold Standard? -- Pharmacokinetics and Pharmacodynamics -- Efficacy of Lithium in Bipolar Disorder -- Carbamazepine -- Valproic Acid -- Mood Stabilizers -- Antipsychotics as Mood Stabilizers -- Administration of Lithium -- The Importance of Patient History -- Suicidality -- Individual Differences and Prediction of Lithium Response in Bipolar Disorder -- Toxicity -- Side Effects -- Polyuria and Polydipsia -- Tremor -- Mood Stabilizers in Schizoaffective Disorder -- Mood Stabilizers in Unipolar Depression Maintenance Therapy -- Is Lithium in any Sense Specific? -- Clinical Vignettes -- References -- Chapter 9: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Deep Brain Stimulation and tDCS -- TMS -- Deep Brain Stimulation (DBS) -- Transcranial Direct Stimulation of the Brain -- Clinical Vignettes -- References -- Chapter 10: Pain Medication and Opiate Addiction -- Treatment of Opiate Addiction -- Side Effects -- Causes of Opiate Addiction -- Clinical Vignettes -- References -- Chapter 11: Stimulant Drugs: Are They Specific for Attention Deficit Disorder or Are They Abused and Overused? -- The Specificity of Stimulants in ADHD -- Effectiveness of Stimulant Treatment in ADHD -- Side Effects of Stimulant Drug Treatment. Psychological Side Effects of Stimulant Treatment -- Comorbidity -- Use of Stimulants for Learning Enhancement -- Long Term Outcomes -- Non Monoamine-Releasing Stimulants -- Use of Stimulants in ADHD Diagnosed Adults -- Pregnancy and Lactation -- How Can Dopamine Enhancement Help with Hyperactivity and Dopamine Reduction Improve Psychosis? -- Vignettes -- References -- Chapter 12: Childhood Psychopharmacology: Modern Parent's Salvation or Danger to the Brains of the Future Generation? -- Enuresis -- Disruptive Mood Dysregulation Disorder -- Autism -- References -- Chapter 13: Drugs for Alzheimer's and Other Dementia: Are they Worth Anything? -- References -- Chapter 14: Drugs for Obsessive Compulsive Disorder: Could Such Obviously Psychological Disorders Have a Pharmacological Treatment? -- Clinical Treatment of OCD -- Side Effects of SSRI Treatment of OCD -- OCD Symptoms in Other Syndromes and in Childhood -- Clinical Vignettes -- References -- Chapter 15: Cannabis: A Useful Psychotropic for Pain, PTSD and Sleep or a Gateway to Schizophrenia? -- Rimonabant and Dronabinol -- Synthetic Cannabinoids -- References -- Chapter 16: Ketamine and Psychedelics in PTSD and Depression: The New Frontier or the New Pandemic? -- Introduction -- Ketamine -- MDMA (Ecstasy) -- Psilocybin -- LSD -- Mechanisms -- References -- Chapter 17: The Placebo Response in Psychopharmacology and the Use of Nutraceuticals in Clinical Psychopharmacology -- The Placebo Response in Psychopharmacology -- Neurotransmitter Precursors -- Omega - 3 Fatty Acids -- Inositol -- Folic Acid -- Niacin -- References -- Chapter 18: Sexual Psychopharmacology: Important Symptomatic Treatment in Depression and Anxiety? -- Erectile Dysfunction -- Side Effects -- Clinical Use -- Sildenafil Abuse -- Rapid Ejaculation (PE) -- Women and PDE-5 Inhibiters and SSRIs. Testosterone for Male and Female Sexual Dysfunction -- HRT -- Transgender Treatment -- Sexology, Psychopharmacology and Psychiatry -- Clinical Vignettes -- References -- Chapter 19: Neuropsychopharmacology: Huntington's, Parkinson's, Tardive Dyskinesia, Narcolepsy, Migraine, Tourette's and Schizophrenia-Like Psychosis of Epilepsy -- Huntington's -- Narcolepsy -- Parkinson's -- Tardive Dyskinesia -- Migraine -- Tourette's Syndrome -- Schizophrenia-like Psychosis of Epilepsy -- References -- Chapter 20: Medication for Eating Disorders: By Popular Demand? -- Obesity -- Anorexia Nervosa -- Bulimia -- Conclusions -- References -- Chapter 21: Pharmacological Treatment of Alcohol Abuse: A Short Chapter -- Introduction -- References -- Chapter 22: Is There a Potential for New Treatments in Psychopharmacology or Have We Picked All the Low Hanging Fruit? -- RHB -- PL -- References -- Chapter 23: Learning and Teaching Psychopharmacology: A resident's Point of View -- Antidepressants and Sexual Psychopharmacology -- Antipsychotics -- Mood Stabilisers -- OCD -- Anxiety -- Stimulants and Children -- Clinical Trials, Diagnosis, Placebo and the Future -- Concluding Remarks -- References -- Index. |
| Record Nr. | UNINA-9910767551503321 |
|
Belmaker Robert Haim
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The role of neuroplasticity in the response to drugs / / editors: David P. Friedman, Doris H. Clouet
| The role of neuroplasticity in the response to drugs / / editors: David P. Friedman, Doris H. Clouet |
| Pubbl/distr/stampa | Rockville, Maryland : , : U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, , 1990 |
| Descrizione fisica | 1 online resource (xii, 211 pages) : illustrations |
| Collana |
NIDA research monograph
DHHS publication |
| Soggetto topico |
Neuropharmacology
Neuroplasticity Drug abuse - United States |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910712028603321 |
| Rockville, Maryland : , : U.S. Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute on Drug Abuse, , 1990 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Serotonin and memory / / edited by Alfredo Meneses and Antonella Gasbarri
| Serotonin and memory / / edited by Alfredo Meneses and Antonella Gasbarri |
| Autore | Alfredo Meneses |
| Pubbl/distr/stampa | Frontiers Media SA, 2016 |
| Descrizione fisica | 1 online resource (129 pages) : illustrations (black and white, and colour); digital file(s) |
| Disciplina | 612.8042 |
| Collana | Frontiers Research Topics |
| Soggetto topico |
Serotonin
Serotonin - Receptors Memory Memory disorders Neuropharmacology Neurosciences |
| Soggetto non controllato |
Learning
5-Hydroxytryptamine forgetting Memory dysfunctional memory neuropsychiatric disorders Amnesia neural markers 5-HT receptors 5-HT markers |
| ISBN | 9782889198023 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910136797303321 |
|
Alfredo Meneses
|
||
| Frontiers Media SA, 2016 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Neuropharmacology
(69)
- Psychopharmacology (13)
- Neuropharmacologie (12)
- Neurology (10)
- Neuropsychopharmacology (10)